Healthcare M&A Erupts as Institutions Flee Software: The Sector Rotation That's Reshaping 2026

Healthcare M&A Becomes the Acquisition Goldmine

Eli Lilly soared over 3.5% after acquiring Orna Therapeutics for $2.4 billion in an all-cash deal, signaling the healthcare sector's explosive M&A momentum. This transaction exemplifies a broader institutional pivot: while software stocks face existential threats from AI automation, healthcare companies are aggressively deploying capital into acquisitions, particularly in biotech and specialty therapeutics.

While pharma volume is down, healthcare services are seeing a bounce-back in large, strategic deals, and biopharma deal value has surged, supported by massive "firepower" from large life sciences companies. The sector has become a capital deployment machine, with major players like Lilly racing to fill pipeline gaps before patent cliffs arrive.

The Institutional Divergence: Healthcare Gains as Tech Retreats

The S&P 500 is down about 16 points (0.24%), while the Nasdaq slips 116 points (0.46%), revealing a critical divergence. US stocks started the week lower as markets continued to assess risks around software stocks following their recent rout, with Intuit and Salesforce falling over 2% each.

Meanwhile, healthcare is attracting institutional capital at an unprecedented pace. Between October 1 and November 17, more cash flowed into health care than into any of the other 10 market sectors, and this momentum has continued into February. Institutional investors are repositioning portfolios toward stable dividend-paying stocks, reducing risk while maintaining upside exposure.

Analyst Conviction Builds on Healthcare Fundamentals

Bank of America reiterated a buy rating on Nvidia with a $275 price target based on 28x CY27E PE, justified by Nvidia's leading share in fast growing AI compute/networking markets, but the real conviction is building in healthcare. Improving earnings clarity, easing policy pressures and accelerating M&A activity are positioning the sector for a more constructive outlook in 2026 and beyond.

Biotechnology leads M&A activity with 35 deals in 2025 year-to-date, making it the busiest sector by a wide margin, with banks following at 15 deals and software close behind at 14. This shift reflects a fundamental reallocation: capital is flowing toward sectors with tangible earnings power, not speculative AI narratives.

What This Means for Your Portfolio

The midday action reveals two distinct market regimes emerging. Healthcare's combination of M&A firepower, institutional inflows, and policy tailwinds creates a structural advantage over software, which faces disruption uncertainty. Communication Services, Industrials and Health Care remain Outperform, based on their generally solid fundamentals and potential ability of the first two to benefit from artificial intelligence adoption.

Investors should monitor healthcare equipment, specialty pharma, and biotech M&A targets. The sector's defensive characteristics, combined with aggressive capital deployment, suggest relative outperformance through midterm election dynamics and beyond.